SCYX
SCYNEXIS, Inc. NASDAQ Listed May 2, 2014$3.98
+4.74%
vs $3.80
Mkt Cap $25.0M
52w Low $3.73
3.6% of range
52w High $10.48
50d MA $6.33
200d MA $6.22
P/E (TTM)
—
EV/EBITDA
—
P/B
4.0x
Debt/Equity
0.0x
ROE
-17.4%
P/FCF
-35.9x
RSI (14)
21.10
ATR (14)
$0.34
Beta
1.15
50d MA
$6.33
200d MA
$6.22
Avg Volume
274.6K
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
1 Evertrust Plaza · Jersey City, NJ 07302-6548 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | AMC | 0.13 | 0.25 | +97.3% | 0.78 | -4.5% | +2.3% | +0.9% | +7.5% | +4.6% | -0.8% | — |
| Nov 5, 2025 | AMC | -0.21 | -0.17 | +19.0% | 0.63 | -2.8% | -5.5% | -0.2% | +0.8% | +0.1% | -1.7% | — |
| Aug 13, 2025 | AMC | -0.23 | -0.14 | +39.1% | 0.85 | +2.5% | -5.1% | +4.8% | -4.5% | -1.6% | +3.8% | — |
| May 15, 2025 | AMC | -0.23 | -0.17 | +26.1% | 0.98 | -8.9% | -19.3% | +5.3% | -3.9% | -3.6% | -0.1% | — |
| Mar 12, 2025 | AMC | -0.22 | -0.09 | +59.1% | 0.91 | -0.5% | -5.9% | +8.6% | +18.0% | -4.5% | +1.9% | — |
| Nov 6, 2024 | AMC | -0.20 | -0.06 | +70.0% | 1.32 | -0.8% | +0.8% | -1.5% | -1.5% | +3.9% | -3.7% | — |
| Aug 8, 2024 | AMC | -0.19 | -0.30 | -57.9% | 1.91 | -1.0% | -7.9% | +0.0% | -1.7% | -4.6% | +4.8% | — |
| May 8, 2024 | AMC | -0.18 | -0.15 | +16.7% | 1.84 | +7.6% | +2.2% | +3.2% | +5.2% | -3.4% | +14.7% | — |
| Mar 28, 2024 | AMC | 0.31 | -0.39 | -225.8% | 1.47 | +3.4% | +1.4% | -2.7% | +24.1% | -6.7% | +1.8% | — |
| Nov 13, 2023 | AMC | 0.29 | -0.04 | -113.8% | 1.72 | +0.3% | -0.3% | -2.9% | -4.8% | +2.5% | +1.9% | — |
| Aug 14, 2023 | AMC | 1.55 | 2.46 | +58.7% | 2.80 | +15.4% | -1.8% | -2.9% | +3.7% | +6.1% | +5.1% | — |
| May 11, 2023 | AMC | -0.28 | -0.25 | +10.7% | 2.75 | +1.5% | +1.1% | +0.0% | +5.0% | -2.1% | +0.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 28 | Guggenheim | Maintains | Buy → Buy | — | $0.75 | $0.76 | +0.9% | -5.0% | -3.9% | +0.0% | -3.9% | -3.2% |
| Aug 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.80 | $3.23 | +15.4% | -1.8% | -2.9% | +3.7% | +6.1% | +5.1% |
| Apr 3 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $3.00 | $3.03 | +1.0% | +22.3% | -4.1% | +1.1% | -2.5% | -4.9% |
| Apr 3 | Guggenheim | Maintains | Buy → Buy | — | $3.00 | $3.03 | +1.0% | +22.3% | -4.1% | +1.1% | -2.5% | -4.9% |
| Mar 1 | Guggenheim | Maintains | Buy → Buy | — | $1.49 | $1.60 | +7.4% | +16.1% | +0.0% | +1.7% | -4.0% | +0.0% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.87 | $1.93 | +3.2% | +10.7% | +1.0% | +2.4% | -0.9% | -0.9% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.02 | $4.00 | -0.5% | -2.7% | -1.0% | -1.0% | +0.0% | -1.3% |
| Jun 7 | Aegis Capital | Maintains | Buy → Buy | — | $8.04 | $8.05 | +0.1% | +5.2% | -1.5% | -0.6% | -1.7% | -0.2% |
| Apr 12 | Aegis Capital | Maintains | Buy → Buy | — | $8.43 | $8.40 | -0.4% | -2.6% | -6.2% | +0.9% | +0.0% | -0.5% |
| Jan 22 | Guggenheim | Maintains | Buy → Buy | — | $7.31 | $8.86 | +21.2% | +10.9% | -5.1% | -4.3% | -6.0% | +5.5% |
| Jan 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.26 | $7.94 | +9.4% | +2.5% | +4.4% | -0.3% | +1.4% | -2.3% |
| Dec 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.14 | $7.28 | +2.0% | +3.5% | -0.7% | -0.8% | +5.1% | -6.3% |
| Nov 25 | WBB Securities | Maintains | Speculative Buy → Buy | — | $6.15 | $5.90 | -4.1% | +10.7% | -0.9% | -1.5% | -3.9% | +4.9% |
| Nov 25 | Maxim Group | Maintains | Buy → Buy | — | $6.15 | $5.90 | -4.1% | +10.7% | -0.9% | -1.5% | -3.9% | +4.9% |
| Nov 25 | Aegis Capital | Maintains | Buy → Buy | — | $6.15 | $5.90 | -4.1% | +10.7% | -0.9% | -1.5% | -3.9% | +4.9% |
| Apr 23 | Aegis Capital | Maintains | Buy → Buy | — | $8.37 | $8.26 | -1.3% | -0.8% | +0.2% | +9.6% | +5.2% | +2.2% |
| Oct 16 | Maxim Group | Maintains | Buy → Buy | — | $11.60 | $11.80 | +1.7% | -3.4% | -4.5% | -1.9% | -1.9% | -5.8% |
| Jun 27 | Maxim Group | Maintains | Buy → Buy | — | $17.00 | $18.10 | +6.5% | -3.5% | +0.6% | -0.6% | +3.0% | +2.4% |
| May 24 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $15.90 | $17.20 | +8.2% | +8.8% | +0.6% | +2.3% | -2.2% | +3.4% |
| Apr 10 | Seaport Global | Maintains | Buy → Buy | — | $12.50 | $13.00 | +4.0% | +1.6% | +0.8% | +1.6% | -1.5% | -0.8% |
| Oct 24 | Guggenheim | Maintains | Buy → Buy | — | $18.30 | $19.50 | +6.6% | +6.6% | -3.1% | -1.6% | +2.2% | +3.7% |
| Jan 31 | Aegis Capital | Maintains | Buy → Buy | — | $30.05 | $30.20 | +0.5% | +0.5% | -1.3% | -2.0% | +4.8% | +2.9% |
| Oct 20 | H.C. Wainwright | Maintains | Buy → Buy | — | $36.40 | $39.50 | +8.5% | +3.3% | -2.9% | -1.6% | +3.1% | +0.0% |
| Oct 7 | WBB Securities | Maintains | Buy → Buy | — | $48.20 | $52.20 | +8.3% | +2.9% | -1.0% | -7.3% | -5.5% | -4.2% |
| Oct 7 | WBB Securities | Upgrade | Buy → Strong Buy | — | $48.20 | $52.20 | +8.3% | +2.9% | -1.0% | -7.3% | -5.5% | -4.2% |
| Aug 17 | Guggenheim | Maintains | Buy → Buy | — | $20.60 | $25.50 | +23.8% | +25.7% | +8.1% | +0.0% | +7.9% | -6.0% |
| Aug 9 | WBB Securities | Maintains | Speculative Buy → Buy | — | $20.90 | $22.20 | +6.2% | -2.4% | +2.0% | +3.8% | +0.0% | -0.9% |
| Mar 28 | Brean Capital | Maintains | Buy → Buy | — | $41.40 | $45.90 | +10.9% | +6.3% | -7.5% | +0.7% | -1.7% | +0.5% |
| Dec 29 | WBB Securities | Maintains | Speculative Buy → Buy | — | $58.20 | $64.70 | +11.2% | +0.7% | +5.3% | +0.6% | -1.8% | -2.5% |
| Jun 10 | Needham | Maintains | Buy → Buy | — | $87.50 | $99.00 | +13.1% | +1.1% | -1.7% | +0.8% | +2.6% | +2.2% |
| Jun 2 | JMP Securities | Maintains | Market Perform → Perform | — | $84.00 | $83.50 | -0.6% | +1.2% | -0.2% | -0.4% | -0.5% | -0.7% |
| May 29 | Canaccord Genuity | Maintains | Buy → Buy | — | $82.00 | $87.00 | +6.1% | -2.0% | +4.5% | +1.2% | -0.2% | -0.4% |
| May 29 | RBC Capital | Maintains | Outperform → Outperform | — | $82.00 | $87.00 | +6.1% | -2.0% | +4.5% | +1.2% | -0.2% | -0.4% |
No insider trades available.
8-K · 8.01
!! High
SCYNEXIS, Inc. -- 8-K 8.01: Material Event / Announcement
May 22
8-K · 5.02
!!! Very High
SCYNEXIS, Inc. -- 8-K 5.02: Executive Change
SCYNEXIS director Steven C. Gilman's decision not to seek re-election reduces board size, potentially affecting governance oversight and decision-making capacity at the biopharmaceutical company.
Apr 20
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
SCYX's equity issuance dilutes existing shareholders' ownership stakes and future earnings per share, likely pressuring the stock price unless the capital raised funds transformative growth or debt reduction.
Mar 31
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
SCYX disclosed a corporate presentation, signaling potential strategic updates or investor communications, warranting attention for material announcements affecting company direction or financial outlook.
Mar 31
8-K · 2.01
!!! Very High
Unknown — 8-K 2.01: Acquisition Completed
SCYX completed a significant asset acquisition that could expand its operational capabilities and revenue streams, making it important for investors to monitor integration success and synergy realization.
Mar 31
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Heights Capital Management, Inc | 2,086,960 | $2M | New | Mar 2026 |
| 2 | Avidity Partners Management Lp | 2,081,660 | $2M | New | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 1,564,398 | $1M | New | Mar 2026 |
| 4 | Acadian Asset Management Llc | 731,952 | $670K | Added | Mar 2026 |
| 5 | Millennium Management | 622,161 | $570K | New | Mar 2026 |
| 6 | Renaissance Technologies Llc | 224,640 | $206K | Added | Mar 2026 |
| 7 | Yakira Capital Management, Inc. | 188,602 | $173K | Reduced | Mar 2026 |
| 8 | Citadel Advisors Llc | 130,831 | $120K | Added | Mar 2026 |
| 9 | Northern Trust Corp | 95,577 | $88K | Added | Mar 2026 |
| 10 | Nierenberg Investment Management Company, Llc | 75,555 | $69K | — | Mar 2026 |
| 11 | Morgan Stanley | 92,190 | $58K | Added | Dec 2025 |
| 12 | Raymond James Financial Inc | 35,180 | $32K | Added | Mar 2026 |
| 13 | Bank Of New York Mellon Corp | 28,846 | $26K | Reduced | Mar 2026 |
| 14 | Susquehanna International Group, Llp | 27,807 | $25K | Reduced | Mar 2026 |
| 15 | Hrt Financial Lp | 26,340 | $24K | New | Mar 2026 |
| 16 | Pds Planning, Inc | 15,000 | $14K | — | Mar 2026 |
| 17 | Jane Street Group, Llc | 14,892 | $9K | New | Dec 2025 |
| 18 | Us Bancorp \de\ | 3,100 | $2K | — | Dec 2025 |
| 19 | Northwestern Mutual Wealth Management Co | 2,487 | $2K | — | Dec 2025 |
| 20 | Royal Bank Of Canada | 820 | $1K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 5
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 223,820 | $168K | Feb 2026 |
| 2 | EA Bridgeway Omni Small-Cap Value ETF | 123,697 | $113K | Mar 2026 |
| 3 | Fidelity Total Market Index Fund | 66,663 | $50K | Feb 2026 |
| 4 | Fidelity Series Total Market Index Fund | 53,118 | $40K | Feb 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 22,803 | $17K | Feb 2026 |
Valuation
Market Cap
$25.0M
Enterprise Value
$168.5M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.06x
P/B
4.03x
P/S
9.77x
P/FCF
-35.92x
EV/EBITDA
—
Shares Out
49.9M
Financials (TTM)
Revenue
$20.3M
Net Income
-$24.5M
EBITDA
-$24.5M
Free Cash Flow
-$5.3M
Op Cash Flow
-$5.3M
EPS Basic
$-0.17
EPS Diluted
$-3.58
EPS Forward
$-0.42
Gross Margin
100.0%
Op Margin
-119.9%
Net Margin
-120.5%
Balance Sheet
Total Assets
$59.0M
Total Liab.
$9.7M
Total Equity
$49.4M
Cash
$21.3M
LT Debt
$0
Book Value/Sh
$0.99
Debt/Equity
0.04x
Current Ratio
7.04
Quick Ratio
7.04
Returns & Growth
ROE
-17.4%
ROA
-14.6%
ROIC
-29.9%
Rev Growth YoY
+450.0%
EPS Growth YoY
+61.4%
Price Returns
2W
-8.5%
1M
-24.2%
3M
-6.0%
6M
+2.2%
12M
-19.4%
Technicals
52W High
$10.48
52W Low
$3.73
50d MA
$6.33
200d MA
$6.22
RSI (14)
21.10
ATR (14)
$0.34
Beta
1.15
Avg Volume
275K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 27, 2026 12:30am
· Source: financialmodelingprep.com